title: Schistosoma haematobium infection levels determine the effect of praziquantel treatment on anti-schistosome and anti-mite antibodies.
abstract: Field studies show an association between schistosome infection and atopy, but the effects of anti-helminthic treatment on this association have not yet been investigated in human populations with different schistosome endemicity levels. This study aimed to compare the effects of anti-helminthic treatment on responses directed against the house dust mite Dermatophagoides pteronyssinus (Derp1) and Schistosoma haematobium in Zimbabwean populations living in high and low schistosome infection areas. Derp1- and schistosome-specific IgE and IgG4 antibodies were quantified by ELISA before and 6 weeks after anti-helminthic treatment. Following treatment, there were changes in the immune responses, which varied with place of residence. After allowing for the effects of sex, age and baseline infection intensity, there was no significant treatment effect on the change in anti-schistosome IgE and IgG4 in the high infection area. However, the anti-schistosome IgE/IgG4 ratio increased significantly, while anti-Derp1 IgE responses decreased as a result of treatment. In the low infection area, treatment resulted in a significant increase in anti-worm IgE levels, but there was no significant treatment effect on anti-schistosome or anti-Derp1 IgE/IgG4 ratios. Thus, the study shows that the level of schistosome endemicity affects the host responses to schistosome and mite antigens following anti-helminthic treatment.
authors.affiliation: Institute of Immunology and Infection Research, Centre for Infectious Diseases, School of Biological Sciences, University of Edinburgh, Ashworth Laboratories, Edinburgh, UK. n.rujeni@sms.ed.ac.uk
authors.forename: N
authors.initials: N
authors.lastname: Rujeni
authors.forename: N
authors.initials: N
authors.lastname: Nausch
authors.forename: N
authors.initials: N
authors.lastname: Midzi
authors.forename: T
authors.initials: T
authors.lastname: Mduluza
authors.forename: D W
authors.initials: DW
authors.lastname: Taylor
authors.forename: F
authors.initials: F
authors.lastname: Mutapi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage*; D000906:Antibodies / Q000097:blood*; D002648:Child; D040002:Dermatophagoides pteronyssinus / Q000276:immunology*; D019353:Endemic Diseases; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D011223:Praziquantel / Q000008:administration & dosage*; D015995:Prevalence; D012548:Schistosoma haematobium / Q000276:immunology*; D012553:Schistosomiasis haematobia / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology*; D055815:Young Adult; D015030:Zimbabwe / Q000453:epidemiology
chemical_list: D000871:Anthelmintics; D000906:Antibodies; D007074:Immunoglobulin G; D007073:Immunoglobulin E; D011223:Praziquantel